Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$2.72
-2.9%
$2.64
$0.91
$4.12
$251.78M2.192.08 million shs1.03 million shs
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
$2.38
+8.7%
$1.51
$2.35
$11.55
$70.81M-0.39486,688 shs803,871 shs
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$4.00
-2.4%
$3.05
$0.73
$4.41
$262.65M0.82291,405 shs155,299 shs
Humacyte, Inc. stock logo
HUMA
Humacyte
$1.50
-5.1%
$2.21
$1.15
$7.48
$250.23M1.96.26 million shs2.49 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
0.00%-7.59%-11.11%+80.65%-27.65%
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
0.00%+25.26%+60.81%+101.69%-60.33%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
0.00%+14.85%+40.89%+220.31%+77.49%
Humacyte, Inc. stock logo
HUMA
Humacyte
0.00%-15.96%-37.55%-37.55%-77.52%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
4.0447 of 5 stars
3.14.00.04.30.62.50.6
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
2.3987 of 5 stars
3.50.00.00.03.83.30.0
Humacyte, Inc. stock logo
HUMA
Humacyte
2.1052 of 5 stars
3.52.00.00.01.41.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
2.23
Hold$5.1087.50% Upside
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
0.00
N/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
3.00
Buy$6.0050.00% Upside
Humacyte, Inc. stock logo
HUMA
Humacyte
3.00
Buy$10.64609.52% Upside

Current Analyst Ratings Breakdown

Latest ELYM, HUMA, GALT, and EDIT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/15/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$3.00 ➝ $5.00
8/14/2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
8/13/2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$4.00 ➝ $6.00
8/12/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $3.50
8/12/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$4.00 ➝ $3.00
8/11/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
7/23/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
7/9/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/17/2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
6/9/2025
Humacyte, Inc. stock logo
HUMA
Humacyte
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
$32.31M7.57N/AN/A$1.63 per share1.67
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/AN/AN/AN/A$3.90 per shareN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/A($1.68) per shareN/A
Humacyte, Inc. stock logo
HUMA
Humacyte
$1.57M151.31N/AN/A($0.41) per share-3.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$237.09M-$2.85N/AN/AN/A-608.88%-200.25%-68.57%11/3/2025 (Estimated)
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
-$35.12M-$0.53N/AN/AN/A-47.03%-45.97%N/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$47.05M-$0.64N/AN/AN/AN/AN/A-225.32%11/13/2025 (Estimated)
Humacyte, Inc. stock logo
HUMA
Humacyte
-$148.70M-$0.45N/AN/AN/AN/AN/A-78.26%N/A

Latest ELYM, HUMA, GALT, and EDIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.16-$0.12+$0.04-$0.12N/AN/A
8/12/2025Q2 2025
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
-$0.41-$0.63-$0.22-$0.63$1.81 million$3.58 million
8/11/2025Q2 2025
Humacyte, Inc. stock logo
HUMA
Humacyte
-$0.15-$0.24-$0.09-$0.24$0.94 million$0.30 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/AN/AN/AN/AN/A
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
Humacyte, Inc. stock logo
HUMA
Humacyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
N/A
2.77
2.77
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
N/A
60.41
60.41
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A
1.43
1.43
Humacyte, Inc. stock logo
HUMA
Humacyte
2.97
2.45
1.93

Institutional Ownership

CompanyInstitutional Ownership
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
71.90%
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
69.76%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
11.68%
Humacyte, Inc. stock logo
HUMA
Humacyte
44.71%

Insider Ownership

CompanyInsider Ownership
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
1.90%
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
4.70%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
50.10%
Humacyte, Inc. stock logo
HUMA
Humacyte
5.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Editas Medicine, Inc. stock logo
EDIT
Editas Medicine
23089.92 million88.21 millionOptionable
Eliem Therapeutics, Inc. stock logo
ELYM
Eliem Therapeutics
929.75 million28.35 millionNot Optionable
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
964.06 million31.97 millionOptionable
Humacyte, Inc. stock logo
HUMA
Humacyte
150158.37 million150.30 millionOptionable

Recent News About These Companies

Wall Street Zen Downgrades Humacyte (NASDAQ:HUMA) to Sell
What is HC Wainwright's Estimate for Humacyte Q3 Earnings?
FY2029 EPS Estimates for Humacyte Cut by HC Wainwright
HC Wainwright Cuts Humacyte (NASDAQ:HUMA) Price Target to $3.00
Durham biotech sees stock plunge on slow sales

New MarketBeat Followers Over Time

Media Sentiment Over Time

Editas Medicine stock logo

Editas Medicine NASDAQ:EDIT

$2.72 -0.08 (-2.86%)
Closing price 04:00 PM Eastern
Extended Trading
$2.76 +0.04 (+1.47%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Eliem Therapeutics stock logo

Eliem Therapeutics NASDAQ:ELYM

$2.38 +0.19 (+8.68%)
As of 08/22/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$4.00 -0.10 (-2.44%)
Closing price 04:00 PM Eastern
Extended Trading
$4.00 +0.00 (+0.12%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Humacyte stock logo

Humacyte NASDAQ:HUMA

$1.50 -0.08 (-5.06%)
Closing price 04:00 PM Eastern
Extended Trading
$1.53 +0.03 (+2.00%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.